DEUCRAVACITINIB

Deucravacitinib is a selective TYK2 inhibitor modulating IL23/IL12 signaling for psoriasis. Side effects include nasopharyngitis, elevated liver enzymes, headache, and acne. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

DEUCRAVACITINIB demonstrates a highgranularity biochemical interaction profile spanning catalyticdomain modulation, multilayer signalling interference, mitochondrialnetwork recalibration, redoxstate restructuring, ionflux redistribution, membraneelectrochemical modulation, cytoskeletalarchitecture remodelling and transcriptionfactor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotidebinding cavities, redox-buffer modules and polymeric scaffolding proteinsenabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, DEUCRAVACITINIB may reshape phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3KAKT survivalpathway architecture, alter Gprotein coupling logic, redistribute Ca²⁺ microdomains, shift IP/DAG signal amplitude, and recalibrate cAMPPKA oscillatory behaviour. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity shifts and ERmitochondria bidirectional stresssignal integration.

Advanced

  • Kinomescale catalyticcascade interference and pathway reconstruction
  • Ultraresolution receptor/ligand docking and conformationaltransition modelling
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crosstalk research
  • Deep multiomics network reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tensionmapping, polymer turnover and mechanosignalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machinelearning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidantbuffer system collapse
  • Mitochondrial fragmentation, membranepotential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ionhomeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • membrane-integrity failure and lipidbilayer thinning
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C20H22N8O3

Molecular Weight

425.5 g/mol

CAS Number

1609392-27-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Deucravacitinib; 1609392-27-9; BMS-986165; Sotyktu; N0A21N6RAU

IUPAC/Chemical Name

6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide

InChl Key

BZZKEPGENYLQSC-FIBGUPNXSA-N

InChl Code

InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3

References

https://pubchem.ncbi.nlm.nih.gov/compound/134821691;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download